Hadadi Ibrahim, Adam Mohamed, J Musa Mustafa, Gareeballah Awadia, Alqahtani Mansour, Kanbayti Ibrahem, Hazazi Ahmed
Department of Radiological Sciences, College of Applied Medical Sciences, King Khalid University, Abha, Asir, Saudi Arabia.
Department of Applied Radiologic Science, University of Jeddah, Jeddah, Saudi Arabia.
Curr Med Imaging. 2025;21:e15734056354807. doi: 10.2174/0115734056354807241217043210.
Type 2 diabetes Mellitus (T2DM) increases vulnerability to metabolic dysfunction-associated steatotic liver disease (MASLD). Therefore, this study aims to determine the prevalence and coexistence of MASLD in patients with T2DM using ultrasound.
This cross-sectional retrospective study included 168 patients with T2DM from multiple diabetes clinics in Abha City, Asir region, recruited between August 2023 and December 2023. Adult patients aged 18 and over with T2DM were included, and data was extracted from patient files. All patients were examined by ultrasound to determine the prevalence and coexistence of MASLD in patients with T2DM. Hepatic steatosis on Bmode ultrasound is qualitatively classified on a four-point scale: normal (0), mild (1), moderate (2), and severe (3).
Out of 168 patients, 68.4% were identified with MASLD, mostly with diffuse liver (97.4%) diagnosed through ultrasound. MASLD was significantly higher in individuals with uncontrolled diabetes (72.5%) than those with controlled diabetes (46.2%), with a significant difference (p=0.015) and an odds ratio (OR) of 3.081, indicating uncontrolled diabetics are over three times more likely to develop MASLD. The uncontrolled group had a statistically significant larger liver size than the control group (13.6cm ±1.43 vs. 13.0cm ±1.20, respectively: [p=0.032, 95%CI 0.053-1.12]). Furthermore, a notable association was observed between increased BMI and the prevalence of MASLD in individuals with T2DM. Furthermore, no significant association was found between the duration of diabetes and the severity of MASLD, nor between the grading of MASLD and gender.
This study highlights a crucial association between uncontrolled diabetes and increased MASLD prevalence, emphasizing the importance of diabetes management in reducing MASLD risk.
2型糖尿病（T2DM）会增加患代谢功能障碍相关脂肪性肝病（MASLD）的易感性。因此，本研究旨在通过超声确定T2DM患者中MASLD的患病率及并存情况。
这项横断面回顾性研究纳入了2023年8月至2023年12月期间从阿西尔地区阿卜哈市多家糖尿病诊所招募的168例T2DM患者。纳入年龄在18岁及以上的成年T2DM患者，并从患者病历中提取数据。所有患者均接受超声检查，以确定T2DM患者中MASLD的患病率及并存情况。B超下肝脏脂肪变性按四分制进行定性分类：正常（0）、轻度（1）、中度（2）和重度（3）。
在168例患者中，68.4%被诊断为MASLD，其中大部分通过超声诊断为弥漫性肝病（97.4%）。糖尿病未得到控制的个体中MASLD的患病率（72.5%）显著高于糖尿病得到控制的个体（46.2%），差异有统计学意义（p = 0.015），优势比（OR）为3.081，表明未控制的糖尿病患者发生MASLD的可能性是前者的三倍多。未控制组的肝脏大小在统计学上显著大于对照组（分别为13.6cm ±1.43和13.0cm ±1.20：[p = 0.032，95%CI 0.053 - 1.12]）。此外，观察到T2DM患者中BMI升高与MASLD患病率之间存在显著关联。此外，未发现糖尿病病程与MASLD严重程度之间以及MASLD分级与性别之间存在显著关联。
本研究突出了未控制的糖尿病与MASLD患病率增加之间的关键关联，强调了糖尿病管理在降低MASLD风险方面的重要性。
